A sensor device is provided for the detection of an occurrence and/or a concentration and/or an amount of an analyte in a sample. The device includes a sensor, connection electronics and a housing. The sensor is configured to convert chemical and/or biochemical information from an analyte, preferably a virus, in a sample to an electrical signal. The sensor includes a test cantilever having a base and a deformable part, where a receptor layer for selective uptake of the analyte has been applied at least atop the deformable part. The sensor further includes a reference cantilever having a base and a deformable part, where a reference layer for selective non-uptake of the analyte has been applied atop the deformable part.

The present invention generally pertains to methods of enriching charge variants of a protein of interest. In particular, the present invention pertains to the use of normal polarity or reverse polarity imaged capillary isoelectric focusing and iterative fractionation to enrich charge variant species of interest.

A method of taking a skin sample can include placing an adhesive onto a portion of skin and lifting the adhesive from the skin. A skin sample may then be tested while still on the adhesive, for example, by inoculating the sample with a bacterium, fungus, virus, or a combination.

Embodiments of a recombinant Respiratory Syncytial Virus (RSV) G ectodomain are provided. Also disclosed are nucleic acids encoding the RSV G ectodomain and methods of producing the RSV G ectodomain. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for inhibiting a RSV infection in a subject by administering an effective amount of the recombinant RSV G ectodomain to the subject to produce a protective immune response.

Currently, the steps performed prior to release of influenza strains to vaccine manufacturers involve passaging influenza virus through eggs. The invention aims to provide procedures useful in manufacturing influenza vaccines, in which the use of eggs is reduced, and preferably is avoided altogether. For instance, rather than use chicken eggs for influenza vaccine isolation, MDCK cells (Madin Darby canine kidney cells) may be used e.g. growing in suspension, growing in a serum-free medium, growing in a protein-free medium, being non-tumorigenic, grown in the absence of an overlay medium, etc.

The invention relates to a diagnostic use of an African Swine Fever Vims CD2v protein, a method, a device, and a kit for the detection of the presence of ASFV antibodies in a test sample, in particular the use thereof in a DIVA immunoassay.

The present invention relates to a peptide that specifically recognizes a protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or a portion thereof; a composition for preventing or treating SARS-CoV-2 infection, comprising the peptide; and a composition for detecting SARS-CoV-2, comprising the peptide.

Compounds and compositions, their use and methods using the compounds and compositions for preventing an infection, e.g. an infection by a virus or bacterium, or treating an infection, e.g. a virus or bacterial infection, or treating a disease caused by an infection, e.g. a virus or bacterial infection, and a method of increasing the binding of virus neutralizing antibodies, an in vitro method of detecting virus-specific antibodies in a sample obtained from a subject, a compound for use in a method of detecting of virus-specific antibodies in a subject, and a kit for the detection of virus-specific antibodies.

An object of the present invention is to provide: a monoclonal antibody that makes it possible that adenovirus contained in a test specimen is detected and measured rapidly, simply, and with high-sensitivity; and an immunoassay for adenovirus and an immunoassay device therefor, for both of which the monoclonal antibody is used. The present invention provides: a monoclonal antibody or an antigen-binding fragment thereof, including heavy chains CDR1 to CDR3 as shown in the following (a) to (c) and a light chain CDR1 as shown in the following (d); and an immunoassay and an immunoassay device, for both of which the monoclonal antibody or the antigen-binding fragment thereof is used; (a) a heavy chain CDR1 composed of an amino acid sequence containing NY; (b) a heavy chain CDR2 composed of an amino acid sequence containing SN; (c) a heavy chain CDR3 composed of an amino acid sequence containing SYY and DY; and (d) a light chain CDR1 composed of an amino acid sequence containing NG.

Pseudotyped lentiviral vector particles bearing a SARS-CoV-2 S protein and comprising a heterologous polynucleotide that encodes a label or a recombinase. Compositions or kits comprising the pseudotyped lentiviral vector particles and a mammalian cell expressing an Angiotensin-converting Enzyme 2 (ACE2) protein. Methods of assaying for the presence of neutralizing antibodies against a SARS-CoV-2 S protein in a sample comprising antibodies by providing pseudotyped lentiviral vector particles bearing a SARS-CoV-2 S protein and comprising a heterologous polynucleotide that encodes a label or a recombinase; providing mammalian cells expressing an ACE2 protein; contacting the mammalian cells expressing the ACE2 protein with the pseudotyped lentiviral vector particles bearing a SARS-CoV-2 S protein in the presence of a sample comprising antibodies; and assaying for the presence of a label in the mammalian cells.